Login to Your Account

Omni Bio chases chance to bring recombinant AAT to patients

By Michael Fitzhugh
Staff Writer

Friday, January 23, 2015

Riding high on new interim data suggesting plasma-derived alpha-1 antitrypsin might help patients with graft-vs.-host disease recover when steroids fail, Omni Bio Pharmaceutical Inc. is angling to produce an irresistible proof-of-concept package showing its preclinical recombinant AAT could do the same and more.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription